{"id":"NCT02515305","sponsor":"Padagis LLC","briefTitle":"Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07","primaryCompletion":"2016-04","completion":"2016-06","firstPosted":"2015-08-04","resultsPosted":"2020-11-16","lastUpdate":"2021-11-08"},"enrollment":890,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne"],"interventions":[{"type":"DRUG","name":"Clindamycin and Benzoyl Peroxide Gel (combination)","otherNames":[]},{"type":"DRUG","name":"Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)","otherNames":[]},{"type":"DRUG","name":"Placebo gel (combination)","otherNames":[]}],"arms":[{"label":"Test product","type":"EXPERIMENTAL"},{"label":"Reference product","type":"ACTIVE_COMPARATOR"},{"label":"Placebo product","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment acne vulgaris","primaryOutcome":{"measure":"Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions","timeFrame":"Baseline to Day 84","effectByArm":[{"arm":"Test Product","deltaMin":71.05,"sd":29.823},{"arm":"Reference Product","deltaMin":72.84,"sd":26.926},{"arm":"Placebo Product","deltaMin":51.53,"sd":28.403}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":385},"commonTop":[]}}